Back to top
more

TherapeuticsMD (TXMD)

(Delayed Data from NSDQ)

$1.52 USD

1.52
14,306

0.00 (0.00%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $1.52 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy

by Zacks Equity Research

TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Chinook (KDNY) delivered earnings and revenue surprises of 1.61% and 83.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -34.86% and 1.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 2.47% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 0.00% and 1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.00% and -1.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TherapeuticsMD (TXMD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50.00% and 6.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

TherapeuticsMD (TXMD) closed the most recent trading day at $1.63, moving +1.24% from the previous trading session.

TherapeuticsMD (TXMD) Surges: Stock Moves 6.8% Higher

by Zacks Equity Research

TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

TherapeuticsMD (TXMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: TherapeuticsMD (TXMD) Q3 Earnings Expected to Decline

by Zacks Equity Research

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

TherapeuticsMD (TXMD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -13.33% and -10.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?